Jove
Visualize
Contact Us

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Searching for a Serological Correlate of Protection for a CMV Vaccine.

The Journal of infectious diseases·2018
Same author

Cytomegalovirus Vaccines: Current Status and Future Prospects.

Drugs·2016
Same author

Non-immune hydrops fetalis caused by herpes simplex virus type 2 in the setting of recurrent maternal infection.

Journal of perinatology : official journal of the California Perinatal Association·2013
Same author

Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2013
Same author

Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV.

Virology·2010
Same author

Recent advances in herpesvirus genetics using bacterial artificial chromosomes.

Molecular genetics and metabolism·2001
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 3, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

Cytomegalovirus vaccine development.

M R Schleiss1

  • 1Division of Pediatric Infectious Diseases, Department of Pediatrics, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, 2001 6th Street SE, Minneapolis, MN 55455, USA. schleiss@umn.edu

Current Topics in Microbiology and Immunology
|July 22, 2008
PubMed
Summary
This summary is machine-generated.

Developing a human cytomegalovirus (HCMV) vaccine remains challenging due to unclear immune correlates and target populations. Further research and public education are crucial for preventing HCMV disease.

More Related Videos

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing
12:21

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing
12:21

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing

Published on: January 7, 2019

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Human cytomegalovirus (HCMV) infection is widespread but can cause severe disease in high-risk groups like transplant recipients, HIV-infected individuals, and fetuses.
  • Despite over 30 years of vaccine development efforts, no licensed HCMV vaccine is available.
  • Immunity to HCMV can reduce disease severity, highlighting the need for effective vaccines.

Purpose of the Study:

  • To review strategies explored for HCMV vaccine development.
  • To summarize current clinical trials and novel technologies for HCMV vaccine research.
  • To address the challenges hindering the licensure of an HCMV vaccine.

Main Methods:

  • Review of historical and ongoing HCMV vaccine development strategies.
  • Analysis of challenges in clinical trials and target population identification.
  • Exploration of novel technologies for future vaccine considerations.

Main Results:

  • Key challenges include unclear immune correlates of protection and uncertainty regarding essential viral vaccine components.
  • Clinical trials have often focused on populations not relevant to preventing congenital HCMV infection.
  • Insufficient public and targeted education about HCMV infection persists.

Conclusions:

  • Successful HCMV vaccine development requires clarifying protective immunity and identifying optimal vaccine targets.
  • Future efforts must consider diverse populations, including pregnant women and the general public.
  • Novel technologies and enhanced public awareness are essential to overcome hurdles in HCMV prevention.